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Abstract
Complicated skin and soft tissue infections (cSSTI) are common and frequently require treatment in hospital. Comprehensive current data
on management practices in patients hospitalized with cSSTI are limited. REACH was a retrospective, observational cohort study designed
to provide data on current clinical management of moderate to severe cSSTI in European hospitals. Data were collected via an electronic
case report form from 129 sites in ten European countries. The study population comprised patients ≥18 years, hospitalized between
March 2010 and February 2011 with cSSTI who received intravenous antibiotic treatment. Presented here is an analysis of the disease
characteristics, treatment patterns during hospitalization and clinical outcomes identiﬁed by the study. The total population included 1995
patients (mean age 60.6 years; 57.7% male). Initial antibiotic treatment modiﬁcation was reported in 39.6% (n = 791) of patients; it was
more common in patients with co-morbidities (42.6%), those requiring surgical intervention (43.4%), those with more severe infections
such as bacteraemia (51.6%) or with fascia affected (49.0%), those admitted to the intensive care unit (56.2%) and those with
lesions > 50 cm2 (44.3%). A switch to narrower-spectrum antibiotic treatment (streamlining) occurred in 5.6% of patients. Mean length of
hospital stay was 18.5 days (19.9; median 12.0) and the total mortality rate was 3.4%. The data collected in REACH give a comprehensive
and current view of real-life clinical management of cSSTI in European hospitals and provide evidence of a high rate of initial antibiotic
treatment modiﬁcation.
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Abstract
Coeliac disease is characterized by intestinal inﬂammation caused by gluten, proteins which are widely contained in the Western diet.
Mammalian digestive enzymes are only partly capable of cleaving gluten, and fragments remain that induce toxic responses in patients with
coeliac disease. We found that the oral microbiome is a novel and rich source of gluten-degrading organisms. Here we report on the
isolation and characterization of the cultivable resident oral microbes that are capable of cleaving gluten, with special emphasis on the
immunogenic domains. Bacteria were obtained by a selective culturing approach and enzyme activities were characterized by: (i) hydrolysis
of paranitroanilide-derivatized gliadin-derived tripeptide substrates; (ii) gliadin degradation in-gel (gliadin zymography); (iii) gliadin
degradation in solution; (iv) proteolysis of the highly immunogenic a-gliadin-derived 33-mer peptide. For selected strains pH activity proﬁles
were determined. The culturing strategy yielded 87 aerobic and 63 anaerobic strains. Species with activity in at least two of the four assays
were typed as: Rothia mucilaginosa HOT-681, Rothia aeria HOT-188, Actinomyces odontolyticus HOT-701, Streptococcus mitis HOT-677,
Streptococcus sp. HOT-071, Neisseria mucosa HOT-682 and Capnocytophaga sputigena HOT-775, with Rothia species being active in all four
assays. Cleavage speciﬁcities and substrate preferences differed among the strains identiﬁed. The approximate molecular weights of the
enzymes were ~75 kD (Rothia spp.), ~60 kD (A. odontolyticus) and ~150 kD (Streptococcus spp.). In conclusion, this study identiﬁed new
gluten-degrading microorganisms in the upper gastrointestinal tract. A cocktail of the most active oral bacteria, or their isolated enzymes,
may offer promising new treatment modalities for coeliac disease.
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